Skip to main content

22-01-2018 | Systemic lupus erythematosus | Review | Article

Treatment of Systemic Lupus Erythematosus (SLE) in Pregnancy

Current Treatment Options in Rheumatology

Authors: BS Erin Shirley, MD, MS Eliza F. Chakravarty

Publisher: Springer International Publishing


To identify known teratogenic medications that may be used to treat SLE and discuss alternative therapeutics that can be used throughout pregnancy in order to manage maternal autoimmune diseases.
Teratogenic immunosuppressive medications include methotrexate, mycophenolatemofetil, and cyclophosphamide. In anticipation of pregnancy, such medications should be discontinued and replaced with immunosuppressive medications including azathioprine and cyclosporine and assessed for disease stability.
Pregnancy is an important aspect to women’s lives, and a diagnosis of SLE should not necessarily preclude the ability to bear children. Pregnancy outcomes among SLE women are favorable when disease is well controlled prior to conception and teratogenic medications are avoided. Several immunosuppressive therapies that are compatible with pregnancy are available to treat flares that may occur during pregnancy. Hydroxychloroquine use throughout pregnancy is associated with improved outcomes for both mother and infant. Risks of medication use need to be balanced with risks of active maternal disease.

Please log in to get access to this content

Related topics